Public web issue
Three FDA records and one narrow price observation for this week's purchase file.
Last updated: 2026-09-08
Public web issue. This edition was not sent by email. No delivery history is implied. Facts were checked against linked records through 2026-09-08.
Fast scan
Verified regulatory record
FDA's September 3 update classifies the software correction as a Class II recall and keeps alternative monitoring in the update instructions.
Verified regulatory record
FDA records K253954 as a traditional 510(k) found substantially equivalent on August 28 for a Class II dental navigation system.
Verified regulatory record
FDA's September 4 update points to a list that the agency explicitly describes as incomplete and tied to public authorization records.
Dated market observation
One Texas DOTmed listing remains visible and marked in stock at a $27,999 asking price for a seller-described 2022 unit.
Source records
Safety record
Verified regulatory record
FDA's September 3 communication says the GE HealthCare Portrait Core Services software issue is now classified as a Class II recall. It covers V1.0.5, V1.1, V1.2, and a V1.1 reload product identified by reference number and UDI on the page.
FDA says that during a service update some patients monitored on Portrait Mobile devices may be discharged from the monitoring system and alarm settings may reset to factory defaults. The page says this can cause loss of patient monitoring or intended alarms at the Hub and Central Viewer.
The instructions call for alternative monitoring before starting an update, retaining the user-manual addendum, and informing potential users. The affected software may continue to be used under the instructions.
Put the exact software version, update procedure, backup, alternative-monitoring plan, post-update patient census and alarm check, addendum, service contact, and completion evidence in the system file.
The communication does not establish failure incidence, predict a specific system's condition, or compare Portrait with another monitor. Its no-serious-injury-or-death statement is a dated company-report status as of July 29, not a rate or guarantee.
Source: FDA GE Portrait Core Services correction
Updated September 3, 2026; accessed September 8, 2026
New clearance
Verified regulatory record
FDA's public records identify K253954 as the X-Guide Surgical Navigation System from X-Nav Technologies, LLC. The traditional 510(k) was found substantially equivalent on August 28, 2026.
The TPLC page identifies the device as a Class II dental navigation system under 21 CFR 872.4120 and product code QRY. FDA defines this device type as providing real-time guidance on the dental instrument's orientation and location relative to patient anatomy for general dentistry procedures.
The reviewed openFDA record lists a summary, but the current direct links did not expose the K253954 summary during the September 8 check. The record therefore supports the clearance fact and classification, not a detailed configuration claim.
Request the current 510(k) summary, exact hardware and software, compatible imaging and instruments, calibration and accuracy checks, training, data export, service, cybersecurity, and transfer terms before comparing the system.
Substantial equivalence is clearance, not approval or proof of a new indication, clinical superiority, workflow fit, service quality, or financial return. Older X-Guide submissions and recalls do not define the K253954 configuration.
Source: FDA TPLC and openFDA K253954 records
Decision August 28, 2026; accessed September 8, 2026
Regulatory resource
Verified regulatory record
FDA's CDRH update index lists the AI-enabled medical device page as updated September 4. The page links listed devices to their marketing-authorization records.
FDA says the list is incomplete. It identifies devices primarily through AI-related terms in public authorization summaries or classifications and says devices without published decision summaries in the collection period may appear later.
During the September 8 check, the newest final-decision date shown in the list was June 29, 2026. The page says FDA will continue periodic updates and explore identification of devices that use foundation models.
For an AI-enabled purchase, start with the exact submission and authorized version, then verify intended use, public summary, validation population, inputs and outputs, human oversight, update policy, cybersecurity, rollback, and postmarket monitoring.
The list is a transparency resource, not a ranking, performance comparison, market census, or complete inventory. Absence does not prove that a device lacks AI, and presence does not validate a vendor's broader claims.
Source: FDA AI-enabled medical device list
Update indexed September 4, 2026; accessed September 8, 2026
Price and ownership signal
Dated market observation
DOTmed listing 4706842 remained visible and marked in stock on September 8 at a $27,999 USD asking price. It describes one used/excellent 2022 InMode Morpheus8 RF Pro in Texas with face and body attachments and a seller-stated 30-day warranty.
Configuration: Seller-described 2022 Morpheus8 RF Pro with face and body attachments.
The repeat check shows listing visibility, not price discovery or buyer demand. Verify the exact platform and serial number, attachments, title, service history, software and consumable eligibility, transfer fees, inspection window, shipping, training, return terms, and warranty provider.
Device Pulse did not inspect the unit, contact the seller, validate the configuration or warranty, or observe a transaction. One visible ask is not a completed sale, range, median, or market price. Continued visibility does not prove buyer interest or rejection.
Source: DOTmed listing 4706842
Listing dated August 7, 2026; accessed September 8, 2026
Open research
Check the FDA communication and recall record for revised software scope, instructions, or status before citing it again.
Open the recordRead the current 510(k) summary before making a configuration, intended-use, or comparison claim.
Open the recordTrack later list updates and device-level authorization records; do not treat absence as evidence that a product lacks AI.
Open the recordBuyer move of the week
Before any device-software update, name the alternative workflow, backup, responsible person, rollback trigger, exact post-update checks, and evidence that the original patient, alarm, user, and integration settings remain correct.
A completed installer screen does not prove that the clinical configuration survived the change. Acceptance should depend on a documented functional check.
Research shortcut
Use the Buyer’s Guide to move from a regulatory signal to exact-device, manufacturer, comparison, and ownership questions without passing through a signup gate.
Open the Buyer’s GuideSend this page to the person who reviews clinical evidence, the person who owns the capital budget, and the person who will manage service calls. Keep the direct source links with the interpretation. A forwarded summary without the identifier, date, configuration, or limitation loses the part that makes it useful.
If a colleague owns an affected unit or has an active quote, ask them to open the live record. FDA recall status and manufacturer instructions can change after an archive date. A company release can be replaced by a later filing. A marketplace listing can change or disappear without proving that a unit sold.
Use the public archive for prior issues, the Buyer’s Guide for device research, the research methodology for evidence rules, and the visible correction section when a material record changes. Signup is optional. This web edition was not sent by email.
No. This is a public web issue. No subscriber list was accessed or contacted.
No. FDA says affected systems may continue to be used under the instructions. Check the exact software version and live communication.
No. FDA records a traditional 510(k) substantial-equivalence decision. That is clearance, not premarket approval or proof of superiority.
No. FDA explicitly describes the list as incomplete and tied mainly to terms in public authorization materials.
No. It is one seller-controlled asking price for one visible listing. No completed sale was observed.
There are none. Results stay unpublished until real responses meet the documented minimum sample and methodology requirements.
Open the printable buyer checklist now, then get the planned Tuesday brief with price, FDA, safety, evidence, and manufacturer signals.
Free kit available immediately. Planned Tuesday brief. Unsubscribe anytime. Privacy.